The Pharma Letter Podcast
Kanal-Details
The Pharma Letter Podcast
The Pharma Letter Podcast provides in-depth discussion and analysis focused on key trends, companies and events in the pharmaceutical and biotech industries. Our guests come from a broad array of sectors and business functions, from early stage research in biopharmaceuticals, to patient engagement a...
Neueste Episoden
34 EpisodenNouscom bets on dual vaccine strategy to outsmart cancer
This week on The Pharma Letter Podcast, we’re joined by Marina Udier, chief executive of Nouscom — a biotech company developing cancer vaccines.
...
Is this a revolution in Alzheimer's?
This week on The Pharma Letter Podcast, we’re joined by Howard Fillit, co-founder and chief science officer at the Alzheimer’s Drug Discovery Foundati...
Why Boehringer and GSK are betting on Ochre
This week on The Pharma Letter Podcast, we’re joined by Quin Wills, co-founder and chief scientific officer of UK biotech Ochre Bio.
A ph...
ICON's AI strategy: faster, smarter trials
This week on The Pharma Letter Podcast, we are joined by Tony Clarke, senior VP of IT digital operations at ICON (Nasdaq: ICLR).
As a leader in...
How real-time data could transform clinical trials
In this week’s podcast, we welcome Iddo Peleg, CEO and co-founder of Yonalink, who provides insights into the current and future state of the clinical...
Japanese pharma in the UK
In this episode, we’ll take a look at the role of Japanese pharmaceutical groups in the UK, with Jackie Davis, general manager at Astellas Pharma.
How can we use AI to program antibodies?
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases.<...
Breakthroughs in MASH, with 89bio CEO
This week we’re focusing on an area of clinical research that has been of great interest for a number of years, that is NASH, also known as MASH.
How to develop cancer drugs faster, with Ellipses Pharma
This week we are speaking with the chief executive of British drug development company Ellipses Pharma.
Founded in 2018 to create new ca...
CRO sector surges in bio revolution
In the world of outsourced clinical research, ICON is a big fish in a pond full of other increasingly big fish.
In this episode of The Ph...
Lilly looks to lead in Alzheimer's
With an Accelerated nod for Aduhelm (aducanumab) and now full approval for Leqembi (lecanemab) in the USA, Biogen (Nasdaq: BIIB) and Eisai (TYO: 4523)...
AAIC preview with Eisai deputy CCO Michael Irizarry
In the runup to the annual meeting of the Alzheimer’s Association, this week we are speaking with Michael Irizarry, deputy chief clinical officer at E...
A new way to innovate, from Flagship Pioneering
Set against a backdrop of foundering confidence in biotech stocks, the success of some companies incubated by Massachusetts-based Flagship Pioneering...
Will radical new EU regs hobble industry?
A draft of the European Commission’s ongoing review of pharmaceutical legislation has leaked, prompting a bitterly-worded reaction from drugmakers, wh...
Galapagos update—with CEO Paul Stoffels
This week on The Pharma Letter Podcast, we are joined by Galapagos (Euronext: GLPG) chief executive Paul Stoffels.
After an illustrious c...
US midterms and beyond: the outlook for pharma
The outcome of the recent midterm elections in the USA surprised many by returning a Democrat-led Senate, preventing Republicans from gaining control...
Focus on rare liver diseases, with Albireo CEO Ron Cooper
*Partnered content
In Boston, Massachusetts, one company is now making significant headway in the development of an innovative treatment...
Inflation Reduction Act: quick take
As President Joe Biden signs the Inflation Reduction Act into law, drugmakers in the USA are poring over the likely impact on drug prices, and how bes...
EQRx plots radical disruption on pricing
For years, commentators have observed that drug prices in the USA are significantly higher than elsewhere in the world.
Pointing to the...
Can AI find new drugs for metabolic diseases?
Interest in the potential for artificial intelligence to transform different aspects of the drug discovery and development process is at an all-time h...
A vaccine for Alzheimer's?
With the approval of Aduhelm (aducanumab), the first new Alzheimer’s treatment in decades, people affected by dementia were given new hope that a brea...
Is there a data capture crisis in biotech?
In recent years there has been an explosion of digital tools and platforms in the life sciences industry, designed to improve processes ranging from d...
Mastering the microbiome
Companies developing microbiome-based treatments have garnered a lot of interest recently, following many years of uncertainty over the therapeutic po...
Should US states control drug prices?
At the national level, drug pricing continues to be a hot button issue for lawmakers, drugmakers and patients in the USA.
For many years,...
Will decentralized clinical trials become the new standard?
This week, we look at the potential impact of decentralized clinical trials.
During the The COVID-19 pandemic, we have seen increased ado...
The rise of AI in drug discovery
In this podcast, we discuss an exciting new collaboration between pharmaceutical majors in the field of AI.
Around the world, ever increa...
Why hasn't the world embraced Sputnik V?
In August 2020, Russia approved its homegrown coronavirus vaccine Sputnik V, months ahead of rival programs in the west.
But despite the...
Better pharma supply chains
In the early days of the coronavirus pandemic, many drugmakers saw major share price declines as investors got to grips with the likely impact on pres...
The importance of patient empowerment in multiple sclerosis care
Patient empowerment is a hot topic in many areas of medicine. Particularly so for diseases that are more complex to manage, and present with symptoms...
Innovation in preleukemia
High-risk MDS, often referred to as preleukemia, is a chronic form of blood cancer with a significant level of unmet medical need.
MDS is...
The state of biotech investing
With all signs pointing to an M&A boom in late 2021 and throughout 2022, our guest will provide valuable insight into current and emerging trends in t...
Psychedelics in medicine
For many years, industry commentators have observed that there could be huge untapped therapeutic potential for psychedelics, should the correct devel...
Non-opioid analgesics
The USA continues to wrestle with the legacy of an epidemic of opioid abuse, believed to have cost the lives of over half a million people through ove...
Belong.Life
Israel-based Belong.Life is the creator of the world’s largest social network for cancer patients, and has ambitions to provide a range of networks ac...